Microfluidic Devices Created from Ordinary, Inexpensive Components
|
By LabMedica International staff writers Posted on 16 Feb 2012 |

Image: NIST scientists combined a glass slide, plastic sheets, and double-sided tape to create an inexpensive and simple-to-build microfluidic device for exposing an array of cells to different concentrations of a chemical (Photo courtesy of Cooksey/NIST).
A glass slide, plastic sheets, and double-sided tape were combined to create a diffusion-based gradient generator, a tool that rapidly assesses how changing concentrations of specific chemicals affect living cells.
Exposing an array of cultured cells to a chemical gradient provides a solution where the chemical concentration changes gradually and predictably across the array. Such gradients are a rapid, high-throughput way to evaluate the effect on cell growth or toxicity.
Created by National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) engineer Javier Atencia the gradient generator is built in layers, with each section precisely positioned with an alignment tab. The base is a glass slide, upon which is attached a strip of double-sided tape cut to have a row of four micrometer-sized channels. On top of this is placed a polystyrene strip cut to have two lines each of four tiny circular "wells" where each pair lines up with the ends of the channel below it. The next layer is another strip of double-sided tape, this time with a Y-shaped canal cut into it to serve as the flow path for the chemical gradient. Finally, a Mylar strip cut to have an identical Y-canal serves as the cover.
The hinged cover allows access to the wells for adding test cells. Once done, the cover is lowered and affixed, sealing the gradient generator. Fluid flow in and out of the system is accomplished using magnetic connectors. Under constant pressure, the flow assures a steady-state stream through the device and creates a diffusion gradient in each buried channel. Cells in the channels are simultaneously exposed to a range of chemical concentrations from high to low.
Conventional microfluidic systems usually mix fluids by pumping them in a circular motion or by twisting and folding them together. The new NIST system's gradient is created by diffusion––the gentle movement of matter from one point to another by random molecular motion. This greatly reduces the risk of cells being swept away or damaged by shearing forces in the test fluid.
The device was tested by loading it with cells genetically engineered to produce large amounts of green fluorescent protein (GFP) and then introduced cycloheximide (CHX), a chemical that shuts down ribosomes, the cell's protein factories. Cells exposed to the toxin quickly stop synthesizing GFP, decreasing fluorescence by an amount directly related to the concentration of CHX.
This is what the scientists observed in the gradient generator assays. The cells were exposed three times to CHX, and each time, the level of GFP fluorescence increased as the concentration of CHX in the gradient decreased, and vice versa.
The new device was described in the 2012 edition of the journal Lab-on-a-Chip.
Related Links:
National Institute of Standards and Technology
Exposing an array of cultured cells to a chemical gradient provides a solution where the chemical concentration changes gradually and predictably across the array. Such gradients are a rapid, high-throughput way to evaluate the effect on cell growth or toxicity.
Created by National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) engineer Javier Atencia the gradient generator is built in layers, with each section precisely positioned with an alignment tab. The base is a glass slide, upon which is attached a strip of double-sided tape cut to have a row of four micrometer-sized channels. On top of this is placed a polystyrene strip cut to have two lines each of four tiny circular "wells" where each pair lines up with the ends of the channel below it. The next layer is another strip of double-sided tape, this time with a Y-shaped canal cut into it to serve as the flow path for the chemical gradient. Finally, a Mylar strip cut to have an identical Y-canal serves as the cover.
The hinged cover allows access to the wells for adding test cells. Once done, the cover is lowered and affixed, sealing the gradient generator. Fluid flow in and out of the system is accomplished using magnetic connectors. Under constant pressure, the flow assures a steady-state stream through the device and creates a diffusion gradient in each buried channel. Cells in the channels are simultaneously exposed to a range of chemical concentrations from high to low.
Conventional microfluidic systems usually mix fluids by pumping them in a circular motion or by twisting and folding them together. The new NIST system's gradient is created by diffusion––the gentle movement of matter from one point to another by random molecular motion. This greatly reduces the risk of cells being swept away or damaged by shearing forces in the test fluid.
The device was tested by loading it with cells genetically engineered to produce large amounts of green fluorescent protein (GFP) and then introduced cycloheximide (CHX), a chemical that shuts down ribosomes, the cell's protein factories. Cells exposed to the toxin quickly stop synthesizing GFP, decreasing fluorescence by an amount directly related to the concentration of CHX.
This is what the scientists observed in the gradient generator assays. The cells were exposed three times to CHX, and each time, the level of GFP fluorescence increased as the concentration of CHX in the gradient decreased, and vice versa.
The new device was described in the 2012 edition of the journal Lab-on-a-Chip.
Related Links:
National Institute of Standards and Technology
Latest Technology News
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more
Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read more
Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more







